Parkinson’s disease is a progressive neurological disorder whose impact extends beyond movement, with implications for functional independence, quality of life, and mortality. Understanding its varied clinical presentation and course is essential to assessing long-term prognosis and mortality risk. This article reviews the classification, pathophysiology, symptoms, diagnosis, and treatment of Parkinson’s disease, with a focus on their relevance to mortality risk assessment.
Definition
Parkinson’s disease (PD) is defined both clinically and pathologically. Clinical manifestations include asymmetric bradykinesia, rigidity, resting tremors, and postural instability. Pathological findings include: (1) a loss of dopaminergic neurons in the substantia nigra pars compacta leading to an overall dopamine deficiency, and (2) intraneuronal aggregation of misfolded α‑synuclein proteins that leads to the formation of Lewy bodies. In addition to the motor symptoms, a multitude of nonmotor symptoms occur in the setting of PD and can precede the onset of motor symptoms by years or decades. Types of nonmotor symptoms include autonomic dysfunction, cognitive impairment, REM sleep behavior disorder (RBD), hyposmia, and constipation.
Classification
Classification of PD by etiology includes sporadic/idiopathic, hereditary, atypical or secondary parkinsonism. Among these etiologies, sporadic/idiopathic cases are the most common and account for approximately 85% of cases.1 PD usually develops after age 60 and often occurs without a clear family history. Features include Lewy body disease on pathology and motor symptoms that precede the onset of dementia by years. Hereditary cases are less common (5%‑10%).2 They typically occur at ages < 50 in those with a positive family history of PD and may or may not develop Lewy body pathology.3
Less common are the atypical parkinsonian syndromes, also known as “Parkinson-plus” syndromes.4 In general, these conditions confer a worse prognosis compared to PD due to the rapid disease progression after symptom onset. Examples include progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration and dementia with Lewy bodies. Acquired causes of parkinsonism include drug-induced (antipsychotics, anti-nausea medications), vascular parkinsonism due to multiple small strokes in the brain, normal pressure hydrocephalus, Wilson’s disease, and brain trauma (most commonly from boxing).
Classification of PD by disease stage starts with preclinical PD, in which there is Lewy body disease present without clinical signs or symptoms. Premotor PD describes the presence of nonmotor symptoms only and is a difficult stage to identify due to the nonspecific nature of these symptoms. Prodromal PD includes nonmotor symptoms with mild motor symptoms (tremor, bradykinesia, rigidity, or postural instability). Clinically established PD occurs when the full Parkinsonian syndrome is present. PD with dementia occurs at least 1 year (and typically many years) after the onset of motor symptoms.5 The last classification stage is dementia with Lewy bodies defined as dementia that begins within one year6 of the onset of motor symptoms.
Pathophysiology
The pathophysiology of PD is marked by a progressive degeneration of dopaminergic neurons in the substantia nigra area of the midbrain. The loss of dopamine production leads to the cardinal motor features of bradykinesia, rigidity, resting tremors, and postural instability. By the time PD symptoms appear, most people have lost 60‑80% or more of the dopamine-producing cells in the substantia nigra.7
In addition to the loss of dopamine production, PD also affects serotonergic, cholinergic, and noradrenergic pathways. Serotonergic dysfunction contributes to mood disturbances, fatigue, sleep disruption, and altered pain processing; cholinergic dysfunction is associated with cognitive impairment, dementia, and gait and balance difficulties; and noradrenergic dysfunction contributes to impaired attention and alertness, mood and sleep disturbances, and autonomic dysfunction. These manifestations reflect overlapping disturbances across multiple neural systems and often respond incompletely to dopamine replacement therapy.
The other key aspect that underlies the pathophysiology of PD is the misfolding of α‑synuclein. This protein regulates neurotransmitter release at nerve endings, sending signals to other neurons or other cells such as muscle or blood vessel cells. The misfolded α‑synuclein protein then forms abnormal fibrils (threadlike fibers) that accumulate with other proteins, lipids and cellular components to form Lewy bodies, the characteristic pathological finding of PD. Once enough Lewy bodies are present, the synaptic function becomes disrupted leading to the motor symptoms of PD. This process spreads across neurons throughout the body leading to disease progression.
So, what is dopamine? This neurotransmitter is a chemical messenger that governs many areas including motor function, cognition, neuroendocrine regulation (e.g., dopamine released from hypothalamus stimulates the pituitary gland to release prolactin), motivation and reward processing. For its role in governing motor function, dopamine is released from the end of a neuron then absorbed into muscle cells via dopamine receptors on the cell surface. Once inside the muscle cell, dopamine regulates motor function by creating smooth, purposeful movements. Dopamine depletion in PD disrupts these motor circuits, which results in difficulty initiating movement, slowness, reduced movement amplitude, and rigidity.
What triggers these pathologic changes? Parkinson’s disease has no single established cause and is thought to arise from interactions among genetic susceptibility, environmental exposures, and age-related cellular dysfunction. These factors may contribute to abnormal alpha-synuclein accumulation and progressive neuronal degeneration, although the initiating cause usually cannot be identified in any one individual.
Signs and Symptoms
Assessing mortality risk associated with PD can be challenging because many nonmotor symptoms appear years before motor symptoms but may be overlooked because of their nonspecific nature. These early symptoms include constipation (most common early symptom), autonomic dysfunction (urinary urgency, orthostatic hypotension), excessive daytime sleepiness and fatigue, depression, and anxiety. Other nonmotor symptoms more specific to PD include hyposmia/anosmia and REM sleep behavior disorder. This latter condition is a parasomnia where a person physically and vocally acts out vivid, often unpleasant dreams during the REM (rapid eye movement) stage of sleep. Symptoms begin years or even decades before the typical motor symptoms of PD develop. The cause is due to the lack of muscle atonia that normally paralyzes skeletal muscles during REM sleep. In addition to PD, this condition is also associated with Lewy body dementia, multiple system atrophy, and narcolepsy.
The motor symptoms of PD include bradykinesia, muscular rigidity, postural instability, masked facies and a unilateral resting tremor often described as “pill-rolling” where the index finger and thumb move as though rubbing a pill between them. Initially, the symptoms can be subtle and don’t interfere with daily activities leading to a delay in diagnosis, especially if the only noted symptom is tremor.
Essential Tremor Versus PD Tremor
Several distinguishing features separate an Essential Tremor from that of PD as per the following table: